299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004511-31-ES
(EUCTR)
31/01/202230/08/2021Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF Cystic Fibrosis and Aspergillus infection
MedDRA version: 20.0;Level: LLT;Classification code 10003488;Term: Aspergillosis;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: NOXAFIL - oral suspension 40 mg/ml
Product Name: Noxafil
Trade Name: Noxafil 100 mg
Product Name: Noxafil
Bambino Gesù Children´s HospitalNULLNot RecruitingFemale: yes
Male: yes
135Phase 2;Phase 3Portugal;France;Czechia;Greece;Spain;Ireland;Netherlands;Germany;United Kingdom;Switzerland;Italy;Sweden
2EUCTR2019-004511-31-DE
(EUCTR)
10/01/202230/07/2021Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF Cystic Fibrosis and Aspergillus infection.
MedDRA version: 20.0;Level: LLT;Classification code 10003488;Term: Aspergillosis;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: NOXAFIL - oral suspension 40 mg/ml
Product Name: Noxafil
INN or Proposed INN: Posaconazole
Other descriptive name: Posaconazole
Trade Name: Noxafil 100 mg
Product Name: Noxafil
INN or Proposed INN: Posaconazole
Other descriptive name: Posaconazole
Bambino Gesù Children's HospitalNULLNot RecruitingFemale: yes
Male: yes
135Phase 2;Phase 3Portugal;France;Czechia;Greece;Spain;Ireland;Netherlands;Germany;United Kingdom;Switzerland;Italy;Sweden
3EUCTR2019-004511-31-NL
(EUCTR)
03/01/202229/04/2021Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF Cystic Fibrosis and Aspergillus infection.
MedDRA version: 20.0;Level: LLT;Classification code 10003488;Term: Aspergillosis;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: NOXAFIL - oral suspension 40 mg/ml
Product Name: Noxafil
Trade Name: Noxafil 100 mg
Product Name: Noxafil
Bambino Gesù Children's HospitalNULLNot RecruitingFemale: yes
Male: yes
135Phase 2;Phase 3Portugal;France;Czechia;Greece;Spain;Ireland;Germany;Netherlands;United Kingdom;Switzerland;Italy;Sweden
4EUCTR2019-004511-31-GR
(EUCTR)
16/09/202104/03/2021Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF Cystic Fibrosis and Aspergillus infection.
MedDRA version: 20.0;Level: LLT;Classification code 10003488;Term: Aspergillosis;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: NOXAFIL - oral suspension 40 mg/ml
Product Name: Noxafil
Trade Name: Noxafil 100 mg
Product Name: Noxafil
Bambino Gesù Children's HospitalNULLNot RecruitingFemale: yes
Male: yes
135Phase 2;Phase 3Portugal;France;Czechia;Greece;Spain;Ireland;Netherlands;Germany;United Kingdom;Switzerland;Italy;Sweden
5EUCTR2019-004511-31-PT
(EUCTR)
18/06/202118/01/2021Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF Cystic Fibrosis and Aspergillus infection.
MedDRA version: 20.0;Level: LLT;Classification code 10003488;Term: Aspergillosis;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: NOXAFIL - oral suspension 40 mg/ml
Product Name: Noxafil
Trade Name: Noxafil 100 mg
Product Name: Noxafil
Bambino Gesù Children's HospitalNULLNot RecruitingFemale: yes
Male: yes
135Phase 2;Phase 3France;Portugal;Czechia;Greece;Spain;Ireland;Netherlands;Germany;United Kingdom;Switzerland;Italy;Sweden
6EUCTR2019-004511-31-FR
(EUCTR)
01/04/2021Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF Cystic Fibrosis and Aspergillus infection.
MedDRA version: 20.0;Level: LLT;Classification code 10003488;Term: Aspergillosis;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: NOXAFIL - oral suspension 40 mg/ml
Product Name: Noxafil
Trade Name: Noxafil 100 mg
Product Name: Noxafil
Bambino Gesù Children's HospitalNULLNot RecruitingFemale: yes
Male: yes
135Phase 2;Phase 3Portugal;France;Czechia;Greece;Spain;Ireland;Netherlands;Germany;United Kingdom;Switzerland;Italy;Sweden
7EUCTR2019-004511-31-GB
(EUCTR)
06/10/2020Prospective validation and clinical evaluation of a new posaconazole dosingregimen for children and adolescents with cystic fibrosis and Aspergillus infection.Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF Cystic Fibrosis and Aspergillus Infection
MedDRA version: 20.0;Level: LLT;Classification code 10003488;Term: Aspergillosis;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Trade Name: Noxafil - oral suspension 40 mg/ml
Product Name: Noxafil - oral suspension 40 mg/ml
Trade Name: Noxafil 100 mg
Product Name: Noxafil 100 mg
Bambino Gesù Children's HospitalNULLNAFemale: yes
Male: yes
135Phase 2;Phase 3Portugal;France;Czech Republic;Greece;Spain;Ireland;Netherlands;Germany;Switzerland;Italy;United Kingdom;Sweden